drugset / Trial / NCT01429038

Mesenchymal Stem Cells After Renal or Liver Transplantation

NCT01429038

Phase 1/2 Completed 40 enrolled University of Liege
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs. Unfortunately, these drugs lead to numerous side effects and fail to prevent the rejection occurring months later after the transplantation (chronic rejection). Recently, it has been shown that a particular type of cells present in the bone marrow, namely Mesenchymal Stem Cells (MSC), when injected to a patient, suppress its immune system and increase success rates of blood cells transplantation. This outcome opens doors to investigate the potential of these cells to provide a valuable tool for improving solid organ transplantation without the need of high concentration of immunosuppressive drugs. The present project aims at evaluating the safety and tolerability of MSC administration after liver or kidney transplantation.

Timeline

Start
2012-02-01
Primary completion
2019-03-11
Completion
2019-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1.5e+06 cells/kg Other
Subject mesenchymal stem cells Cell therapy 3e+06 cells/kg Other